FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551810050> ?p ?o ?g. }

• W1551810050 endingPage "652" @default.
• W1551810050 startingPage "646" @default.
• W1551810050 abstract "<b><i>Summary</i></b><b><i>Background: </i></b>The triplet combination of fluorouracil, oxaliplatin and irinotecan for metastatic colorectal cancer improves efficacy at the cost of increased toxicity. Preliminary reports indicate that triplet combination regimens might improve outcome in the RAS/RAF-mutated subgroup. <b><i>Patients and Methods: </i></b>This retrospective analysis included 25 patients with metastatic colorectal cancer, who received treatment with OCX (oxaliplatin, irinotecan, capecitabine). The regimen consisted of oxaliplatin 70 mg/m² on days 1 and 15, irinotecan 100 mg/m² on days 8 and 22, and capecitabine 1,400 mg/m² on days 1-29 every 5 weeks. KRAS, NRAS, and BRAF mutations were determined by Sanger sequencing. <b><i>Results: </i></b>23 patients received at least 1 cycle and were evaluable for efficacy. In 10 patients, a KRAS or BRAF mutation was detected. Partial remission rate was 61%, median progression-free survival 9.8 months, and median overall survival 32.9 months for all evaluable patients. No difference in efficacy was detected between the RAS/RAF wild-type and the mutant group. OCX was well tolerated with no grade 3/4 haematological events. Diarrhoea was the major non-haematological toxicity (24% grade 3). <b><i>Conclusion: </i></b>In this retrospective analysis, triplet chemotherapy with OCX was well tolerated and achieved encouraging efficacy in metastatic colorectal cancer irrespective of RAS/RAF mutation status." @default.
• W1551810050 created "2016-06-24" @default.
• W1551810050 creator A5014418918 @default.
• W1551810050 creator A5025804381 @default.
• W1551810050 creator A5044116406 @default.
• W1551810050 creator A5045139107 @default.
• W1551810050 creator A5050931392 @default.
• W1551810050 creator A5075026411 @default.
• W1551810050 date "2014-01-01" @default.
• W1551810050 modified "2023-09-25" @default.
• W1551810050 title "Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis" @default.
• W1551810050 cites W1967559066 @default.
• W1551810050 cites W2003157997 @default.
• W1551810050 cites W2044796029 @default.
• W1551810050 cites W2048513443 @default.
• W1551810050 cites W2076366897 @default.
• W1551810050 cites W2085633477 @default.
• W1551810050 cites W2098354753 @default.
• W1551810050 cites W2101144899 @default.
• W1551810050 cites W2106845199 @default.
• W1551810050 cites W2118330362 @default.
• W1551810050 cites W2127640925 @default.
• W1551810050 cites W2132598198 @default.
• W1551810050 cites W2134142320 @default.
• W1551810050 cites W2141801755 @default.
• W1551810050 cites W2150266118 @default.
• W1551810050 cites W2157716751 @default.
• W1551810050 cites W2157769714 @default.
• W1551810050 cites W2171576276 @default.
• W1551810050 cites W2171790106 @default.
• W1551810050 cites W2314927739 @default.
• W1551810050 doi "https://doi.org/10.1159/000368313" @default.
• W1551810050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25427581" @default.
• W1551810050 hasPublicationYear "2014" @default.
• W1551810050 type Work @default.
• W1551810050 sameAs 1551810050 @default.
• W1551810050 citedByCount "1" @default.
• W1551810050 countsByYear W15518100502022 @default.
• W1551810050 crossrefType "journal-article" @default.
• W1551810050 hasAuthorship W1551810050A5014418918 @default.
• W1551810050 hasAuthorship W1551810050A5025804381 @default.
• W1551810050 hasAuthorship W1551810050A5044116406 @default.
• W1551810050 hasAuthorship W1551810050A5045139107 @default.
• W1551810050 hasAuthorship W1551810050A5050931392 @default.
• W1551810050 hasAuthorship W1551810050A5075026411 @default.
• W1551810050 hasConcept C121608353 @default.
• W1551810050 hasConcept C126322002 @default.
• W1551810050 hasConcept C143998085 @default.
• W1551810050 hasConcept C2777909004 @default.
• W1551810050 hasConcept C2780259306 @default.
• W1551810050 hasConcept C2780962732 @default.
• W1551810050 hasConcept C2781187634 @default.
• W1551810050 hasConcept C2781413609 @default.
• W1551810050 hasConcept C526805850 @default.
• W1551810050 hasConcept C71924100 @default.
• W1551810050 hasConcept C90924648 @default.
• W1551810050 hasConceptScore W1551810050C121608353 @default.
• W1551810050 hasConceptScore W1551810050C126322002 @default.
• W1551810050 hasConceptScore W1551810050C143998085 @default.
• W1551810050 hasConceptScore W1551810050C2777909004 @default.
• W1551810050 hasConceptScore W1551810050C2780259306 @default.
• W1551810050 hasConceptScore W1551810050C2780962732 @default.
• W1551810050 hasConceptScore W1551810050C2781187634 @default.
• W1551810050 hasConceptScore W1551810050C2781413609 @default.
• W1551810050 hasConceptScore W1551810050C526805850 @default.
• W1551810050 hasConceptScore W1551810050C71924100 @default.
• W1551810050 hasConceptScore W1551810050C90924648 @default.
• W1551810050 hasIssue "11" @default.
• W1551810050 hasLocation W15518100501 @default.
• W1551810050 hasLocation W15518100502 @default.
• W1551810050 hasOpenAccess W1551810050 @default.
• W1551810050 hasPrimaryLocation W15518100501 @default.
• W1551810050 hasRelatedWork W2010163599 @default.
• W1551810050 hasRelatedWork W2010928484 @default.
• W1551810050 hasRelatedWork W2035875009 @default.
• W1551810050 hasRelatedWork W2037813108 @default.
• W1551810050 hasRelatedWork W2051540233 @default.
• W1551810050 hasRelatedWork W2439722139 @default.
• W1551810050 hasRelatedWork W2587690857 @default.
• W1551810050 hasRelatedWork W2617055067 @default.
• W1551810050 hasRelatedWork W349909140 @default.
• W1551810050 hasRelatedWork W2188887532 @default.
• W1551810050 hasVolume "37" @default.
• W1551810050 isParatext "false" @default.
• W1551810050 isRetracted "false" @default.
• W1551810050 magId "1551810050" @default.
• W1551810050 workType "article" @default.